SALT LAKE CITY, Dec. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Company is delivering a presentation at the Point-of-Care Testing 2025 Exhibition and Conference in Boston, MA. The presentation, titled "Exploring the Promise of Portable,...Read more
New data will be presented about Precise® Molecular Residual Disease (MRD) Test and MyRisk® Hereditary Cancer Test SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will present new data in eight abstracts at the 2025 San Antonio Breast Cancer Symposium® (SABCS). The company will share the latest advances in the...Read more
CHICAGO / Dec 09, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that ten abstracts have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS). The meeting takes place December 9–12 at the Henry B. González Convention Center in San Antonio, Texas. “This year at SABCS, our research highlights the power of...Read more
Leading European Hospital System Begins Offering On-site Liquid Biopsy Testing Based on Proprietary Guardant360® CDx Technology PALO ALTO, Calif. & ROME / Dec 09, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the successful launch of FPG 360, an in-house liquid biopsy testing service at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Policlinico...Read more
Real-world Signatera™ analysis and Foresight CLARITY™ results from the HOVON study demonstrate the value of personalized ctDNA testing in therapy response assessment and surveillance AUSTIN, Texas / Dec 09, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today shared the results from two oral presentations that were presented at the American Society of Hematology (ASH) Annual...Read more
Expert panel offers data-driven guidance for integrating DecisionDx-Melanoma into clinical decision-making for patients with melanoma FRIENDSWOOD, Texas, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of an independent expert consensus paper titled “31-Gene Expression Profiling for Cutaneous...Read more
VANCOUVER, BC / ACCESS Newswire / December 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT) is advancing the development of a next-generation "Melt in Your Mouth" cladribine formulation, built on the Company's proprietary oral dissolvable film (ODF) drug-delivery system. The technology is designed for rapid, sublingual (under-the-tongue) absorption of medication and aims to improve treatment...Read more
HENDERSON, Nev.,, December 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of two abstracts at the North America Conference on Lung Cancer (NACLC) in Chicago recently. The posters highlighted the use of its Nu.Q® Cancer assays in the management of lung cancer patients. Prognostic Value of Circulating H3K27Me3-Nucleosomes in Newly Diagnosed...Read more
FORT MYERS, Fla. / Dec 08, 2025 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will present new data demonstrating how comprehensive genomic profiling (CGP) can refine diagnosis and guide treatment decisions for patients with myeloid malignancies at the 67th American Society of Hematology (ASH) Annual Meeting, which is being held Dec. 6–9, 2025, in...Read more
Joint study conducted with Memorial Sloan Kettering Cancer Center demonstrates clear, positive impacts on patient care NEW HAVEN, Conn., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) will be presenting at ASH the findings of a joint study conducted with scientific collaborators from Memorial Sloan Kettering in New York, evaluating Precipio’s BCR::ABL1 assay. The data...Read more
Presentations highlight advancements in cancer recurrence detection with Guardant Reveal and real-time treatment response monitoring with Guardant360 Liquid PALO ALTO, Calif. / Dec 05, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present a total of 14 abstracts with its research collaborators from multiple studies demonstrating the value of its tissue-free liquid biopsy tests at...Read more
Expands Natera’s lead in solid tumor MRD, acquiring ultrasensitive phased variant technology with LOD95 of 0.3 parts per million (ppm) and detection below 0.1 ppm1 Cutting-edge IP adds to Natera’s portfolio of >500 issued or pending patents Accelerates Natera’s expansion into lymphoma, where Foresight has developed a strong clinical position AUSTIN, Texas & BOULDER, Colo. / Dec 05, 2025 / Business Wire / Natera, Inc. (NASDAQ:...Read more
HENDERSON, Nev., Dec. 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the inclusion of its Nu.Q® NETs H3.1 assay in "DETECSEPS", a real-world evaluation of early detection of sepsis. DETECSEPS Consortium was awarded winner of the "Challenge Prevention" call for proposals launched by the French Health Innovation Agency and operated by the Banque Publique...Read more
Peer-reviewed JMIR Cardio study demonstrates real-world clinical impact of data-driven digital nudges on hypertension outcomes Data-driven engagement translates to lower health risks and downstream cost savings for Dario clients Results highlight Dario's ability to deliver lasting impact and further cement the Company's position as a proven leader in evidence-based digital care NEW YORK, Dec. 4, 2025 /PRNewswire/ --...Read more
Offering includes Animal Origin-Free Preps, Transfection-Grade Preps and Target Yield with turnaround time starting at four business days for Express Genes Enables nucleic acids therapeutics research, which can include antisense oligonucleotide therapies, gene therapies and more SOUTH SAN FRANCISCO, Calif. / Dec 04, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today...Read more
Feasibility study data at 12-22% liver fat cutoffs validate TAEUS as a potential low-cost, point-of-care alternative to MRI-PDFF for patient stratification and trial monitoring ANN ARBOR, Mich. / Dec 04, 2025 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermo-acoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced new results...Read more
Clinical utility data for Nodify Lung® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer Development data for a new ultra-sensitive ESR1 assay for breast cancer treatment resistance monitoring to be presented at San Antonio Breast Cancer Symposium (SABCS) LOUISVILLE, Ky., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading...Read more
SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) offering CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), announced today that the clinical lab fee schedule (CLFS) for 2026 posted by Centers for Medicare & Medicaid Services (CMS) indicates an increase of 47%, from $1263.53 to $1853.22, for the payment for the...Read more
SAN ANTONIO, Texas / Dec 03, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced that Chief Medical Officer Gordon Downie, MD, PhD, will present a poster at the American Cancer Society National Lung Cancer Roundtable (NLCRT) showcasing three cases in which CyPath® Lung, a noninvasive sputum-based flow...Read more
Largest real-world dataset of personalized circulating tumor DNA (ctDNA) across lymphoma subtypes showed Signatera was prognostic of outcomes and outperformed imaging in detecting recurrence AUSTIN, Texas / Dec 03, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced that new data on Signatera will be presented at the 2025 American Society of Hematology (ASH) Annual...Read more
Fourth quarter fiscal 2025 revenue up 5.9% to $138.1 million Fiscal 2025 revenue increased 4.5% to $513.0 million Fourth quarter fiscal 2025 operating loss decreased 48.5% to $6.8 million Fiscal 2025 operating loss decreased 64.2% to $30.9 million Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research...Read more
LINCOLN, Neb. & ST. JOSEPH, Mo. / Dec 02, 2025 / Business Wire / Mosaic Life Care, a physician-led health system located in northwest Missouri, announced a new partnership with NRC Health, the leader in healthcare experience management. Together, the organizations will work to elevate patient and employee experience across Mosaic’s system, reinforcing its vision for Mosaic to be the region’s first choice and most trusted partner in...Read more
RESEARCH TRIANGLE PARK, N.C. / Dec 02, 2025 / Business Wire / IQVIA (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced a strategic collaboration with Amazon Web Services (AWS), naming AWS as IQVIA’s Preferred Agentic Cloud Provider. The partnership, revealed at AWS re:Invent, is a major step in the digital...Read more
DNA-based Colorectal Cancer Screening as a Home Test BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company“), molecular genetics diagnostic company specializing in the early detection of cancer, today announced that its test ColoAlert® has been added to the portfolio of DoctorBox, one of Germany’s leading pioneers in digital health. This marks another...Read more
Signatera Genome demonstrated 100% sensitivity and specificity in detecting breast cancer recurrence in the surveillance setting AUSTIN, Texas / Dec 02, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that at least twelve abstracts highlighting Signatera will be shared at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place December 9-12. The...Read more
SANTA CLARA, Calif. / Dec 01, 2025 / Business Wire / Agilent Technologies Inc (NYSE: A) today announced the release of a new 21 CFR Part 11 compliance software for the Agilent xCELLigence Real-Time Cell Analysis (RTCA) eSight system. The software includes a compliance license and enhanced security features, allowing this multiplex live-cell analysis system to be deployed not only in drug discovery and development labs but now also in...Read more
WILMINGTON, Mass. / Dec 01, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Evercore 8th Annual Healthcare Conference on Wednesday, December 3rd, at 10:00 a.m. ET. Management will provide an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted...Read more
Breast Suite is an industry-leading, comprehensive, and modular AI-powered suite of applications supporting more than 10 million mammograms annually delivering increased breast cancer detection rates,1 risk stratification tools, and viewing and reporting workflow acceleration CHICAGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- DeepHealth, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (Nasdaq:...Read more
VANCOUVER, BC / ACCESS Newswire / December 1, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce it has signed a letter agreement with a European-based chemotherapy company (the "Codeveloper") for the exclusive intellectual property rights to a novel sublingual drug formulation using a high-potency active...Read more
Company expands portfolio of novel AI-powered clinical and operational solutions delivering proven impact at scale—empowering breakthroughs in care through imaging CHICAGO, Nov. 30, 2025 (GLOBE NEWSWIRE) -- DeepHealth, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), today unveils an expanded portfolio at RSNA 2025, introducing next-generation imaging informatics and...Read more
Bringing Cholesterol-Lowering Injections to U.K. Community Pharmacies VANCOUVER, British Columbia, Nov. 27, 2025 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “Avricore”) is pleased to announce HealthTab™ is being deployed in a new pilot launched by Barts Health NHS Trust, in collaboration with UCL Partners and the British Heart Foundation (BHF), to deliver inclisiran cholesterol-lowering injections through...Read more
Company engaging in multiple options for a constructive resolution Strategy is underpinned by a clinical study that achieved the agreed upon endpoints Company believes that labeling modifications can address any outstanding concerns SANTA CLARA, Calif. / Nov 26, 2025 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today...Read more
Actionable offering helps enable earlier, more personalized breast cancer interventions BOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Clairity, Myriad Genetics, Inc. (NASDAQ: MYGN), and MagView, today announced a joint collaboration in an effort to identify more women at high risk for breast cancer, with the goal of addressing a critical gap in breast cancer risk assessment without...Read more
HENDERSON, Nev., Nov. 25, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the first sale of its Nu.Q® Cancer assays to one of Europe's leading cancer centers, the Hospices Civils de Lyon, in Lyon, France. Professor Léa Payen, Professor in Toxicology and Biochemistry, Claude Bernard University of Lyon I and Hospices Civils de Lyon, France commented: "We are...Read more
Delivers solid results in Q4, initiates FY26 guidance Fourth-quarter fiscal year 2025 Revenue of $1.86 billion for the fourth quarter ended October 31, 2025, exceeding revenue guidance and representing growth of 9.4% reported and up 7.2% on a core(1) basis compared with the fourth quarter of 2024. GAAP net income of $434 million; earnings per share (EPS) of $1.53, up 25% from the fourth quarter of 2024. Non-GAAP(2) net income of $452...Read more
Third SHORE Publication Highlights HeartCare’s Role in Risk Stratification and Personalized Post-Transplant Care SOUTH SAN FRANCISCO, Calif. / Nov 24, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the publication of...Read more
BEDFORD, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced the presentation of new florbetaben F18 data at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) 2025 conference, taking place December 1-4, in San Diego,...Read more
Sanofi and Symphony Health teams conducted the study demonstrating how Dario's digital, diabetes intervention platform reduces real-world healthcare burden and cost compared to usual care Representing a high-rigor, real world analysis, the study found Dario users, as compared to matched individuals receiving usual care, had 23% lower hospitalization rates and 26% lower all-cause charges More frequent engagement on the Dario platform...Read more
The PRIME study, one of the largest studies on preterm birth, has been accepted for publication by a medical journal following abstract presentation earlier this year SALT LAKE CITY, Nov. 24, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the...Read more
Bulto, President, U.S. of Novartis, brings global healthcare leadership and growth track record to support Labcorp's long-term strategy BURLINGTON, N.C., Nov. 24, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of Victor Bulto, a seasoned pharmaceutical executive and member of Novartis' executive leadership team, to its Board of...Read more
SALT LAKE CITY, Nov. 20, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Company's Executive Vice President of Business Development, Joseph Featherstone, addressed a satellite session of the International Union Against Tuberculosis and Lung Disease (The Union)...Read more
Designed to provide real-time glucose readings for an industry-leading 15.5 days*†, Dexcom G7 15 Day will be available in the U.S. for people over the age of 18 with diabetes beginning on Dec. 1, 2025. Dexcom G7 15 Day will first be available through durable medical equipment (DME) providers with full retail launch in the coming weeks. Dexcom CGM continues to be the most covered and reimbursed CGM brand on the market1. SAN DIEGO /...Read more
TAEUS Liver demonstrates strong agreement with the industry’s imaging gold standard, MRI‑PDFF, across the full spectrum of steatotic liver disease and patient BMI ANN ARBOR, Mich. / Nov 20, 2025 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction-associated liver disease (“MASLD”) and metabolic...Read more
Expect Proteus launch by end of 2026 Demonstration of the detection of all 20 amino acids by end of 2026 New controlled cleavage chemistry unlocks path to billions of sequencing reads BRANFORD, Conn. / Nov 20, 2025 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced the highlights...Read more
Cloud-native platform selected to modernize operations, help improve efficiency and strengthen patient-centered care coordination across multi-site network SOMERVILLE, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- DeepHealth, a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and a leader in AI-powered health informatics, today announced Wichita Radiological Group (WRG) has selected DeepHealth’s Operations Suite™1 to replace its...Read more
VANCOUVER, BC / ACCESS Newswire / November 20, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that the Eurasian Patent Organization (EAPO) has officially granted Patent No. 051510 (issued November 14, 2025). The patent covers the sublingual delivery of anticancer drugs for the treatment of autoimmune...Read more
GUANGZHOU, China, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2025. Recent Business Updates Therapy Selection Presented study results at the Cell Reports Medicine on...Read more
Seasoned healthcare strategy leader to advance The Governance Institute and Market Insights LINCOLN, Neb. / Nov 20, 2025 / Business Wire / NRC Health, the leader in healthcare experience management, today announced the appointment of David Burik as Executive Vice President, Strategic Insights, effective January 5, 2026. David joins NRC Health from Guidehouse, where he has served as partner and leader of the Center for Health Insights,...Read more
Advancing next-generation IMC workflows with class-leading HCR imaging technologies for greater sensitivity and flexibility LOS ANGELES & SAN FRANCISCO / Nov 19, 2025 / Business Wire / Molecular Instruments® (MI), the inventor of the HCR™ imaging platform, and Standard BioTools Inc. (NASDAQ: LAB) today announced a strategic collaboration to develop next-generation Imaging Mass Cytometry™ (IMC™) workflows powered by HCR imaging...Read more
Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers.* Dexcom Smart Basal is FDA cleared and now the first and only CGM-integrated basal insulin dosing optimizer for adults aged 18 and older with Type 2 diabetes who are using long-acting insulin.1 SAN DIEGO / Nov 19, 2025 / Business Wire / DexCom, Inc. (NASDAQ: DXCM), the global leader in...Read more
BRANFORD, Conn. / Nov 19, 2025 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced the key items to be presented at its Investor & Analyst Day that is being hosted in New York City. Among other advances, the management team will provide updates on: Proteus™ platform development...Read more
Studies demonstrate Labcorp Plasma Detect MRD Technology can inform treatment strategies and advance cancer research BURLINGTON, N.C., Nov. 19, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced Labcorp Plasma Detect, a tumor-informed, blood-based assay used to detect molecular residual disease (MRD) from circulating tumor DNA (ctDNA), was...Read more
SALT LAKE CITY, Nov. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has begun clinical evaluations for its Co-Dx™ PCR Flu A/B, COVID-19, RSV Test Kit. The clinical performance testing is expected to support a submission to the United States Food and Drug...Read more
Strategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion, EBITDA Accretion and Cashflow Generation DUBLIN, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has received World Health Organization (WHO) approval for the offshored and...Read more
OncoVanguard8 is a leading service provider for innovative healthcare products for insurance companies operating in Peru, Colombia and Ecuador BERKELEY, Calif. and MAINZ, Germany, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company“), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the signing of a Memorandum of Understanding (“MOU”)...Read more
Largest real-world analysis of AI-driven breast cancer screening in U.S. history1 demonstrates increased cancer detection rate with consistent benefits across patient populations LOS ANGELES and SOMERVILLE, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), the nation's largest provider of outpatient diagnostic imaging services, and its wholly owned subsidiary, DeepHealth, a global leader in AI-powered health...Read more
Preliminary Expected Fourth Quarter 2025 Revenue of $137.5 to $138.5 Million Preliminary Expected Full Year 2025 Revenue of $512.5 to $513.5 Million Updated Time of Company Presentation at Jefferies Global Healthcare Conference WEST LAFAYETTE, Ind., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical...Read more
WILMINGTON, Mass. / Nov 17, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 18th, at 11:30 a.m. GMT (6:30 a.m. ET). Management will provide an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a...Read more
ANN ARBOR, Mich. / Nov 17, 2025 / Business Wire / ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (“MASLD”) and metabolic dysfunction associated steatohepatitis (“MASH”), today provided a business update and reported financial results for the three and nine months ended September 30,...Read more
Over $450,000 Adjusted EBITDA and $275,000 positive operating cash flow for the quarter NEW HAVEN, Conn., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), filed its 10-Q report today. The following are the highlights of the Company’s financial performance and outlook for the remainder of 2025. Q3-2025 Financial Results: Revenues. Q3-2025 revenues reached $6.8M, a 30%...Read more
DUBLIN, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategic collaboration with a leading bioinformatics company to conduct advanced analysis on clinical trial data for EpiCapture, the company’s PCR-based epigenetic liquid biopsy test for monitoring the risk of...Read more
Tempus Launches Its First Study With a Nonprofit Foundation Collaborator to Create Robust FL Dataset CHICAGO / Nov 14, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and being run in collaboration with the Institute for Follicular Lymphoma Innovation (IFLI), a global, nonprofit, private...Read more
Company achieves 86% increase in CyPath® Lung testing revenue, strengthens balance sheet SAN ANTONIO / Nov 14, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on providing noninvasive, accurate detection of early-stage lung cancer and other lung diseases, today reported financial results for the three months ended September 30, 2025. Key Highlights CyPath® Lung revenues...Read more
SOUTH SAN FRANCISCO, Calif. / Nov 14, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the fourth quarter and full year fiscal 2025 ended September 30, 2025. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal fourth...Read more
Second study to be presented at the 2nd European Congress on Dermato-Oncology demonstrates DecisionDx-Melanoma can identify patients with a negative sentinel lymph node who have a higher risk of poor outcomes FRIENDSWOOD, Texas, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating the clinical...Read more
MENLO PARK, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences: Wolfe Research Healthcare Conference 2025 in New York, NY Fireside chat on Tuesday, November 18 at 8:40 AM ET Jefferies Global Healthcare Conference in London, UK Hosting 1x1...Read more
LINCOLN, Neb. / Nov 13, 2025 / Business Wire / NRC Health, the leader in healthcare experience management, is proud to announce a new partnership with BJC Health System, one of the nation’s largest nonprofit integrated healthcare delivery organizations. The collaboration will unify and elevate patient and employee experiences across BJC’s hospitals, clinics, and academic partners, reinforcing its mission to improve the health and well-being...Read more
Toronto, Ontario--(Newsfile Corp. - November 13, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ("Telo" or the "Company"), a leader in diagnostic and prognostic innovation through its proprietary multi-factor telomere analytics, today announced that it will deliver an industry presentation at the 2025 Myeloma Canada MRD Testing Implementation Summit, taking place November 14–15. Dr. Yulia Shifrin, Laboratory Director at Telo...Read more
Company Reports $13.8M in Q3 Revenue as Refocusing and Cost Cutting Initiatives Drive Improved Late Quarter Performance with Accelerated Sequential Improvements Expected in Q4 and into 2026 HALLANDALE BEACH, Fla., Nov. 13, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-commerce...Read more
SALT LAKE CITY, Nov. 13, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2025 ended September 30, 2025. Third Quarter and Recent Highlights: Meaningful progress on payer initiatives, including an inaugural...Read more
Third quarter 2025 revenue was $5.0 million, compared to $7.4 million in the third quarter of 2024, and $5.4 million in the second quarter of 2025 Targeting $12.4 million in new business, reflecting both committed annual recurring revenue ("CARR") and late-stage opportunities nearing completion; 2026 pipeline expanded to $69 million Exceeded 2025 goal of 40 new signed accounts for 2026 revenue, with 45 new signed accounts to...Read more
Conference call to discuss financial and operational results scheduled for Friday, November 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nevada, Nov. 13, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the third quarter ended September 30, 2025. Volition management will host a conference call tomorrow,...Read more
Commercial Readiness Plans Accelerating in Anticipation of FDA 510(k) Clearance for Groundbreaking 12-lead Electrocardiogram (ECG) Synthesis Software for Arrhythmia Assessment Anticipated FDA Clearance in Q4 2025 is a Major Inflection Point as HeartBeam Evolves into a Commercial-Stage Company Focused on Growth Announced Partnership with HeartNexus to Provide On-Demand Cardiologist Reviews of Synthesized 12-Lead ECGs for Arrhythmia...Read more
SALT LAKE CITY, Nov. 13, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Diagnostics," "Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Business Highlights: Performed in-silico analysis of the primer sets used in its...Read more
Conference call today, November 13, 2025, at 4:30 PM ET SAN DIEGO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2025. “Over the last year, we have taken decisive steps to transform our business model by focusing on driving consumables and software utilization among our existing routine use customers. We believe our performance in...Read more
Collaboration aims to expand existing U.S. relationship combining GE HealthCare’s mammography systems with DeepHealth’s Breast Suite to include a worldwide distribution arrangement Intends to integrate GE HealthCare’s ultrasound imaging with DeepHealth’s AI-powered Thyroid Suite for intelligent clinical decision support and advanced automation Creates a proposed offering combining DeepHealth’s remote scanning solution, TechLive™,...Read more
Q3 revenues increased by 18% to $27.4 million Adjusted EBITDA profitability of $1.0 million for Q3 Acquisition of ExoDx business from Bio-Techne Corporation Conference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA – November 12, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for...Read more
Initiates Full Year 2025 Revenue Guidance of $173.0 Million to $173.5 Million MOUNTAIN VIEW, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today reported financial results for the three months ended September 30, 2025. Third Quarter 2025 Highlights Total revenue of $46.3 million, a 41% increase...Read more
Study shows that rare variants captured by Illumina WGS with DRAGEN™ variant calling explain most of the "missing heritability" in complex human diseases and traits, including those related to blood pressure and cholesterol Results demonstrate the advantages of WGS over WES and genotyping arrays for assessing genetic risk and identifying drug target candidates. SAN DIEGO, Nov. 12, 2025 /PRNewswire/ -- A study published today in...Read more
New Policy Update Brings Innovative, Non-Drug Depression Treatment to Adolescents Across 26 States MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, announced that TriWest, the regional...Read more
Analysis based on claims data highlights significant cost savings, especially among high-risk members NEW YORK, Nov. 12, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the presentation of research on new real-world evidence of medical cost reduction at ISPOR Europe 2025, one of the world's premier health economics and outcomes...Read more
34-member consortium creates an interoperable data standard for AI and distributed analytics Notable founding members include Guardant Health, NetApp, Seagate, IBM, DDN, and Genentech PALO ALTO, Calif. / Nov 12, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the public launch of the Single Namespace Working Group (SNS), a 34-member, cross-industry consortium which has...Read more
First-of-its-kind, automated system delivers increased sensitivity, specific identification of disease markers and improved laboratory workflow to support fast, confident diagnoses WALTHAM, Mass. / Nov 12, 2025 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced 510(k) clearance of the EXENT® Analyser and Immunoglobulin Isotypes (GAM) Assay**, a first-of-its-kind automated...Read more
BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in MEDICA 2025, one of the world’s leading healthcare trade shows, taking place from 17–20 November, 2025, in Düsseldorf, Germany. With over 5,000 exhibitors from 70 countries...Read more
Streamlined electronic access now available for Natera’s clinical oncology portfolio across Flatiron Health’s network of 4,500+ cancer care providers AUSTIN, Texas / Nov 12, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point-of-care solutions in oncology, today announced the...Read more
DUBLIN / Nov 12, 2025 / Business Wire / ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation, today announced that Mr. Barry Balfe, CEO of ICON plc and Mr. Nigel Clerkin, CFO of ICON plc, will present at the Jefferies London Healthcare Conference on Wednesday, November 19, 2025 at 9:00 am GMT. Any changes to this event and links to the live webcast (where available) will be posted on the Investor section of our website...Read more
WASHINGTON, Nov. 11, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Jefferies Global Healthcare Conference in London, UK on Tuesday, November 18, 2025 at 11:00 a.m. GMT. The event will be simultaneously webcast on www.danaher.com. ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to...Read more
SAN DIEGO, Nov. 11, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Wolfe Research Healthcare Conference 2025 on November 19, 2025Fireside chat at 6:20am Pacific Time (9:20am Eastern Time) The webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com. A replay will be posted on...Read more
Drives efficiency and reliability in Quality Control and Development environments, integrating seamlessly with world-class Empower™ Chromatography Data System (CDS). Mitigates CDS communication errors encountered in up to 70% of multi-vendor LC-CAD configurations.1 Delivers near-universal detection of an expansive range of analytes across pharmaceutical formulations, food additives, and environmental pollutants, including...Read more
FRIENDSWOOD, Texas, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, Dec. 2, 2025, at 1:10 p.m. Eastern time. A live audio webcast of the Company’s presentation will be available by...Read more
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE